PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

NCT03543813 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Head and Neck Cancer
Non Small Cell Lung Cancer
Diffuse Large B Cell Lymphoma
Esophageal Cancer

Interventions

DRUG: CX-2029

Sponsor

CytomX Therapeutics